New Coverage

Wedbush initiates coverage on Omeros Corp. (Nasdaq: OMER) with an Outperform rating and a $12 fair value estimate.

The firm notes that Omeros' lead product candidate, OMS103HP, "controls multiple components of inflammation and associated tissue damage occurring throughout the surgical procedure while standard of care is only a relatively modest perioperative intervention." Wedbush also cites two other candidates which are currently in clinical development, OMS302 and OMS201.

Wedbush feels that Omeros will provide positive Phase 3 results on OMS103HP sometime in mid-2010, likely showing improved patient recovery post arthroscopic ACL surgery.

Despite the new Outperform rating, shares of Omeros are trading about 0.7% lower to $7.65.

Omeros Corporation, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing products on inflammation and disorders of the central nervous system.

Davenport initiates coverage on C&F Financial (Nasdaq: CFFI) with a Buy rating and a $23.50 price target.

The firm notes that while returns have been down compared to recent years, it points out that "when compared to peers CFFI has delivered better than most." Davenport is attracted to C&F's "diverse
geographic base, lower risk markets and multiple business lines" that "have allowed the company to navigate the past several tough quarters relatively well."

C&F Financial Corporation operates as the holding company for Citizens and Farmers Bank that provides various banking and related financial services.

JANCO Partners iinitiates coverage on IMAX Corp (Nasdaq: IMAX) with a Buy rating. Price target $14.

JANCO analyst says, "With a likely increase in consistently released content which can be enhanced from the IMAX experience, we believe a second IMAX theater in many zones, or even multiplexes, is feasible over the next few years. The JV revenue sharing model (lower capex for exhibitors) is a key enabler for what should be an increasing slate of films in 2D and 3D which are well matched for the IMAX experience...Our price target represents a premium to the film exhibitors and is generally inline with large film studio EBITDA multiples. IMAX has greater pricing and margin leverage than the exhibitors, and more predictable film performance at the box office vs. the film studios (selectively picking franchise titles for IMAX in a win-win for the film studios)."

To see all the upgrades/downgrades on shares of IMAX, visit our Analyst Ratings page.

IMAX Corporation, together with its subsidiaries, operates as an entertainment technology company worldwide.

Barclays initiates coverage on AGCO Corporation (Nasdaq: AGCO) with an Equalweight rating. Price target $32.

To see all the upgrades/downgrades on shares of AGCO, visit our Analyst Ratings page.

AGCO Corporation (AGCO) is a manufacturer and distributor of agricultural equipment and related replacement parts.

Wunderlich Securities initiates coverage on EXCO Resources (NYSE: XCO) with a Buy rating. Price target $22.

EXCO Resources, Inc. (EXCO) is an independent oil and natural gas company engaged in the acquisition, development and exploitation of onshore North American oil and natural gas properties.

To see all the upgrades/downgrades on shares of XCO, visit our Analyst Ratings page.